₹250 per dose."GAVI via its Strategic Investment Fund, will provide at-risk funding of a further $150 million, bringing the total funding provided through this collaboration to $300 million," the company said in a statement.“At this stage, it is important for governments, global health and financial institutions in the public and private sector to come together in ensuring that no one is left behind in the road to recovery.
This association is in line with our efforts to see that the future vaccines reaches the remotest part of the world providing full immunization coverage in a bid to contain the spread of the pandemic," said Adar Poonawalla, CEO of Serum Institute of India."The funding will support at-risk manufacturing by SII for.